Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 3/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | GPR3 | P46089 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8248035 | 0.79 | ALDH1A1 (0.38) | KIF11ALDH1A1TSHRHPRT1POLB | |
| SCHEMBL6562728 | 0.79 | HPRT1 (0.46) | GPR3ALDH1A1TSHRHPRT1TDP1 | |
| SCHEMBL30366540 | 0.79 | HPRT1 (0.46) | GPR3ALDH1A1TSHRHPRT1TDP1 | |
| SCHEMBL15958515 | 0.76 | ALDH1A1 (0.39) | CYP11B2CYP11B1KIF11BACE1ALDH1A1 | |
| SCHEMBL6057597 | 0.76 | SLC22A12 (0.39) | ALDH1A1SLC22A12SMN1; SMN2 | |
| SCHEMBL4219687 | 0.75 | SLC6A4 (0.37) | ALDH1A1TSHRHPRT1L3MBTL1SLC6A4 | |
| SCHEMBL3246265 | 0.74 | KIF11 (0.37) | CYP11B2CYP11B1KIF11BACE1ALDH1A1 | |
| SCHEMBL19284577 | 0.74 | IDO1 (0.38) | KIF11BACE1ALDH1A1TSHRPOLB | |
| SCHEMBL6566550 | 0.74 | IDO1 (0.59) | KIF11TSHRTDP1KDM4EMEN1 | |
| SCHEMBL18244061 | 0.74 | KIF11 (0.37) | KIF11BACE1ALDH1A1TSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116581241-A | Positive electrode plate and preparation method and application thereof | 蜂巢能源科技(无锡)有限公司 | 2023-08-11 | — | — | CN | claimed |
| CN-116581241-A | Positive electrode plate and preparation method and application thereof | 蜂巢能源科技(无锡)有限公司 | 2023-08-11 | — | — | CN | disclosed |
| EP-2079467-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2015-11-18 | — | — | EP | disclosed |
| US-8039484-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039484-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100105725-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2010-04-29 | — | — | US | disclosed |
| US-20100105725-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2010-04-29 | — | — | US | disclosed |
| US-7442808-B2 | e.g. 3-(indan-1-yloxy)-8-(oxazolidin-2,4-dion-5-yl)-5,6,7,8-tetrahydroquinoline; with other active ingredients; agonists of G-protein coupled receptor 40 (GPR40); antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity, hyperlipemia | MERCK & CO., INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442808-B2 | e.g. 3-(indan-1-yloxy)-8-(oxazolidin-2,4-dion-5-yl)-5,6,7,8-tetrahydroquinoline; with other active ingredients; agonists of G-protein coupled receptor 40 (GPR40); antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity, hyperlipemia | MERCK & CO., INC. (US) | 2008-10-28 | — | — | US | disclosed |
| WO-2008054675-A2 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2007136572-A2 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007136573-A2 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070265332-A1 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
| US-20070265332-A1 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
| CN-1019113-B | Process for preparing 3-arylhydrido-3-substituted propanamines | LILLY CO ELI (US) | 1992-11-18 | — | — | CN | disclosed |
| US-5023269-A | 3-aryloxy-3-substituted propanamines | ELI LILLY AND COMPANY (US) | 1991-06-11 | — | — | US | disclosed |
| EP-0273658-B1 | 3-ARYLOXY-3-SUBSTITUTED PROPANAMINES | ELI LILLY AND COMPANY (US) | 1990-10-31 | — | — | EP | disclosed |
| US-4956388-A | ANTIDEPRESSANTS, ANTIANXIETY, TREATMENT OF OBESITY, ADDICTION TO SMOKING AND ALCOHOL | ELI LILLY AND COMPANY (US) | 1990-09-11 | — | — | US | disclosed |
| EP-0273658-A1 | 3-Aryloxy-3-substituted propanamines | ELI LILLY AND COMPANY (US) | 1988-07-06 | — | — | EP | disclosed |
| CN-87108175-A | The propylamine that 3-aryloxy-3-replaces | — | 1988-07-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105725-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | GPR119, FFAR2, GPR65 | CYP11B2 502/4885CYP11B1 521/4885KIF11 4117/4885 |
| US-20070265332-A1 | Antidiabetic bicyclic compounds | GPR119, GPR65, FFAR4 | CYP11B2 256/4885CYP11B1 271/4885KIF11 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.